Amgen Ups Ante With Co-Pay Relief For Patients On TNF Blockers
This article was originally published in The Pink Sheet Daily
Executive Summary
Arthritis drug makers are boarding the bandwagon to woo recession-stricken patients with special offers.
You may also be interested in...
J&J's Intravenous Remicade Grows Despite Tough Times
Implications for anti-TNFs Humira and Enbrel, which tumbled in the first quarter, are unclear.
J&J's Intravenous Remicade Grows Despite Tough Times
Implications for anti-TNFs Humira and Enbrel, which tumbled in the first quarter, are unclear.
Just-Approved Cimzia Set To Enter Tough RA Market
UCB vows to prove skeptics wrong with a swift, successful launch of pre-filled syringes.